How a Copenhagen housing project by a $23 billion Novo-backed firm is rethinking big-city challenges like loneliness and access to sunlight
If you want to address civilization and society's issues, then you have to do it with the city," Urban Partners' co-CEO Claus ...
Fierce Pharma2d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Endpoints News3d
No­vo Nordisk’s rare dis­ease ‘com­pa­ny with­in a com­pa­ny’ has an open goal in sick­le cell
Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...
The Economist3d
The world’s trustbusters hint that they want more deals
Donald Trump’s incoming administration was promising to slash corporate taxes and tear up red tape in the world’s mightiest ...
BioPharma Dive3d
Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy
Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...
Zacks Investment Research on MSN4d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...
Global Microbial Fermentation Technology Market To Increase At A Steady Growth Rate Of ~5% By 2032 | Delveinsight
The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...
Pharmaceutical Technology on MSN6d
Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic deal
Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...
The Joplin Globe6d
Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies
(Gensaic), a biotechnology company that combines AI-powered protein design with biological insights to discover ligands for tissue-selective intracellular delivery, today announced a license and ...